The cryptocurrency-funded peptide market has surpassed a $100 million annual run rate after first-quarter sales jumped 159% QoQ to $32 million, according to a new report from Chainasis.
summary
- Chainalysis says the cryptocurrency-funded peptide market has surpassed a $100 million annual run rate.
- Peptide sales in the first quarter of 2026 jumped 159% QoQ to $32 million.
- Average spending on independent purity testing has fallen by 88% per purchaser, raising safety concerns as demand for peptides continues to grow.
According to Chainalysis, demand for unpatented peptides has rapidly expanded beyond niche biohacking communities, creating a growing gray market industry that increasingly relies on cryptocurrency payments.
The blockchain analytics firm said peptide purchases reached $32 million during the first quarter of 2026, up from $12 million in the previous quarter.
Peptides, short chains of amino acids used in health, fitness and wellness products, have gained attention following the success of GLP-1 drugs such as Ozempic and Wegovy. Increasing consumer interest in weight loss, performance enhancement and recovery products has pushed more buyers toward alternative peptide suppliers that operate outside traditional pharmaceutical channels, Chainalysis said.
Many of these suppliers are based in China, where access to traditional banking services can be limited for companies selling medical compounds and unregulated materials. As a result, Chainalysis said cryptocurrency has become a major payment method that connects manufacturers with international buyers.
Stablecoins have become the preferred payment method
By examining the on-chain activity associated with major peptide vendors, Chainalysis found that major vendors increasingly prefer stablecoins over more volatile cryptocurrencies.
The company said sellers receiving average deposits of at least $1,000 showed a payment mix dominated by stablecoins, indicating an effort to reduce exposure to cryptocurrency price fluctuations while handling larger supply chain transactions.
What started as a small marketplace catering to niche buyers has evolved into a more organized ecosystem, according to Chainalysis.
The report noted that large vendors are adopting increasingly sophisticated on-chain financial practices while continuing to process large volumes through Bitcoin and stablecoins.
Chainalysis compared peptide trading to other gray market industries that have historically turned to cryptocurrencies after facing restrictions from banks and payment processors. The company said suppliers can offer raw, unbranded products directly to consumers at prices significantly lower than those available through regulated channels.
The results also fit into a broader trend previously identified by Chainalysis. Earlier this year, the company I mentioned Cryptocurrency flows to suspected trafficking services rose 85% during 2025, with stablecoin-intensive networks operated by Telegram and other online platforms.
Chainalysis said blockchain’s transparency provides investigators with permanent transaction records that can help track financial activity and identify key intermediaries.
Spending on quality testing has declined despite higher demand
Along with higher sales, Chainalysis identified a decline in spending on independent product testing among peptide buyers.
The company said several customers had previously sent payments to peptide suppliers and to Janošek, a Czech laboratory that tests for chemical purity. As the number of buyers rose, testing expenses failed to keep pace with sales growth.
According to Chainalysis estimates, average spending on testing per buyer has fallen by 88% to about $8, even though Janushek is conducting more tests than before. The decline occurred because new demand entered the market faster than testing activity expanded.
Safety concerns have also emerged about some suppliers involved in the industry. Chainalysis reported that Shanghai Sigma Audley, a company linked to organizations previously involved in the sale of fentanyl precursors, made at least $1 million in bitcoin and $3.59 million in stablecoins before expanding into peptide sales.
Given the mix of unregulated products and cryptocurrency-based transactions, Chainalysis warned that many new clients entering the sector may have limited experience in either market, increasing potential risks as the industry continues to grow.
